Azione ELVN ENLIVEN THERAPEUTICS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Enliven Therapeutics, Inc.

Azioni

ELVN

US29337E1029

Tempo reale stimato Cboe BZX
Altri mercati azionari
 16:29:52 08/07/2024 		Variaz. 5gg Var. 1 gen.
23,1 USD +3,03% Grafico intraday di Enliven Therapeutics, Inc. +2,16% +67,56%
27/06 Un insider di Enliven Therapeutics ha venduto azioni per un valore di 259.902 dollari, secondo un recente deposito SEC MT
11/06 ENLIVEN THERAPEUTICS, INC. : prospettiva positiva di Baird ZM

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!
Registrazione 100% gratuita
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to Russell Microcap Growth Index
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to Russell 2500 Growth Index
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to Russell Small Cap Comp Growth Index
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to Russell 3000E Growth Index
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to Russell 3000 Growth Index
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to Russell 2000 Growth Index
Enliven Therapeutics Insider Sold Shares Worth $259,902, According to a Recent SEC Filing
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to S&P Pharmaceuticals Select Industry Index
Enliven Therapeutics, Inc. Appoints Lori Kunkel to the Committee
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing
Enliven Therapeutics Q1 Loss Narrows
Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors
Enliven Therapeutics, Inc. announced that it has received $90.000014 million in funding
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione ELVN
  4. Notizie Enliven Therapeutics, Inc.
  5. Altre lingue